All for Joomla All for Webmasters

D3 - Session 5 - D-Dimer and Arterial Diseases

Rate this item
(1 Vote)

Did you attend this webinar? Get your certificate

 

Questions/answers on the Session 5 - D-Dimer and Arterial Diseases

A1. Peripheral arterial disease (PAD) is not an area I have extensive experience in. I did not find any relevant paper on the role of D-dimer during an acute event (i.e. as SnOUT test). D-dimer is certainly elevated in acute limb ischemia: however, the diagnosis is mainly based on symptoms and signs (i.e. 5 P of Pratt) associated with vascular imaging.
Kleinegris and colleagues reviewed the literature a few years ago with the aim to assess the value of D-dimer as a predictor of arterial thrombotic events in patients with PAD. An increased D-dimer appeared to be independently associated with a two times increased risk of near-term cardiovascular events (relative risk 2.30, 95% confidence interval 1.43–3.68). However, they concluded that, due to the extended heterogeneity of the included studies, cautious interpretation of these data is warranted. In 2020, Kremers and colleagues aimed to provide a comprehensive overview of biomarker testing in PAD as a first step to improve risk stratification. Forty-seven studies comprising 21 473 PAD patients met inclusion criteria and were included. Patients with increased high-sensitivity CRP (C-reactive protein) levels had a relative risk of 1.86 (1.48-2.33) for major adverse cardiovascular events and a relative risk of 3.49 (2.35-5.19) for mortality. Increased fibrinogen and d-dimer levels were associated with an increased relative risk of mortality of 2.08 (1.46-2.97) and 2.22 (1.24-3.98), respectively. Additionally, patients with increased NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cTnT (cardiac troponin T) levels were at an even higher risk of mortality with relative risks of 4.50 (2.98-6.81) and 3.33 (2.70-4.10), respectively.
In 2008, Vidula and colleagues found that among persons with PAD, circulating levels of D-dimer and inflammatory markers are higher in the 1 to 2 years before death than in periods more remote from death. Increasing levels of D-dimer and inflammatory biomarkers are independently associated with higher mortality in persons with PAD. More recently, McDermott and colleagues found that in PAD patients with an ischemic heart disease event, D-dimer was higher within 2 months of the event, compared to most values obtained 10 to 32 months previously. D-dimer was also higher in cases as compared to controls during most visits within 8 months of the IHD event.

A2. Many Emergency Department’s (ED) patients with chest pain/dyspnea may have different explanations of their symptoms. I know that in many EDs it is a common clinical practice to test biomarkers, such as troponin, NTpro-BNP, and D-dimer without assessing pretest probability of acute coronary syndrome, heart failure, and pulmonary embolism: even if testing biomarkers at admission is simpler and faster, this practice maybe increase the number of patients with a missed diagnosis and increase the number of tests inappropriately and uselessly requested (i.e. false negative and false positive results)

A3. I am not aware of solid evidence on the usefulness of D-dimer in the follow-up of patients with arterial thrombosis. However, I would discourage to use it as a stand-alone test to take any management decision. After a pulmonary embolism/deep vein thrombosis, D-dimer may be useful to stop or continue anticoagulation 3 to 6 months after the acute event, but it is used with other parameters in a multiparametric assessment of risks and benefits.

A4. No guidelines suggest using D-dimer when there is a suspicion of an acute coronary syndrome, and I would discourage using it. As I’ve shown in my presentation, ESC guidelines suggest using it - according to other published dedicated guidelines - in case there is also a concomitant suspicion of pulmonary embolism or aortic dissection, or when acute coronary syndrome has been excluded.

A5. I would suggest the same recommendations as for venous thrombosis. UFH administration should be dosed according to aPTT levels; heparin levels measured as anti-factor Xa activity should be tested when patient has high levels of fibrinogen and/or factor VIII (during an acute phase reaction), aPTT is not sufficently prolonged despite elevated (> 40.000 IU/day) doses of UFH, UFH is administered after a thrombolytic therapy, or when aPTT is already prolongeddue to the presence of LAC, factor deficiency or presence of antibodies.
For LMWH, anti-factor Xa activity should be tested in case of risk of inappropriate LMWH dosage, such as in patients with renal insufficiency, extreme body weights, pregnancy, neonates, children, or prolonged used.

A6. "Thrombophilia" has been developed and tested in patients with venous thrombosis: in particular, inherited factors have been discovered in families with recurrent thrombosis that occurred in young individuals. Arterial thrombosis is often caused by a local factor, i.e. atherosclerosis, and the role of the coagulation system is often less relevant than in venous thrombosis. In case of unexplained arterial thrombosis, it may be useful to perform some tests, in particular antiphospholipid antibodies (i.e. lupus anticoagulant, anticardiolipin antibodies, anti-beta2GPI antibodies) and homocysteine levels. The role of other thrombophilia tests is marginal, and it is not useful to make treatment decisions.

Additional Info

  • Business Line: Hemostasis
  • Language: English
  • Speaker(s): Alessandro Squizzato
  • Recorded Date: Thursday, 06 May 2021
  • Duration: 29:15
Read 2608 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection